Trial intelligence / Profile preview

Azacitidine subcutaneous with or without durvalumab in previously untreated higher-risk MDS or elderly AML ineligible for HSCT

2015-003596-30Phase 2Unknown

Sponsor

Celgene Corporation

Start

Jan 2016

Modality

PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules

Countries

1